These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 37712675)
1. Optimizing patient selection for primary prevention implantable cardioverter-defibrillator implantation: utilizing multimodal machine learning to assess risk of implantable cardioverter-defibrillator non-benefit. Kolk MZH; Ruipérez-Campillo S; Deb B; Bekkers EJ; Allaart CP; Rogers AJ; Van Der Lingen ACJ; Alvarez Florez L; Isgum I; De Vos BD; Clopton P; Wilde AAM; Knops RE; Narayan SM; Tjong FVY Europace; 2023 Aug; 25(9):. PubMed ID: 37712675 [TBL] [Abstract][Full Text] [Related]
2. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465 [TBL] [Abstract][Full Text] [Related]
4. Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction. Muhammed A; Abdelazeem M; Elewa MG; Sharief M; Ammar A Heart Fail Rev; 2023 Jan; 28(1):229-240. PubMed ID: 35587303 [TBL] [Abstract][Full Text] [Related]
5. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease. Wang L; Javadekar N; Rajagopalan A; Rogovoy NM; Haq KT; Broberg CS; Tereshchenko LG Heart Rhythm; 2020 May; 17(5 Pt B):860-869. PubMed ID: 32354451 [TBL] [Abstract][Full Text] [Related]
6. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316 [TBL] [Abstract][Full Text] [Related]
7. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442 [TBL] [Abstract][Full Text] [Related]
8. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]